Phaseline

Companies › Skyhawk Therapeutics

Skyhawk Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Neurology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SKY-0515
Unclear mechanism targeting harmful proteins in Huntington's Disease
–Phase 2Huntington DiseaseMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06873334SKY-0515Phase 2Huntington DiseaseNeurologyMay 2027
NCT07378644SKY-0515Phase 2Huntington DiseaseNeurologyDec 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Dasher Neuroscience ThromBio Appello Pharmaceuticals PhenoNet Glycomine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.